The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Quite. When will the hysteria stop? The guidance is still single digit growth and that Jumpshot will not impact (which is the only thing I find hard to believe). So the figures are no better than when the SP was £3.30 . Slightly overbought I would say as all the director sells in previous months would suggest
AVST website:
We want to reassure our users that at no time have we sold any personally identifiable information to a third party. We want to give confidence to all our users and partners that they have made the right decision to choose Avast and reassure them that their privacy is secure and their personal data safe.
We have always been committed to providing our users with full control of their privacy at every turn. Our Privacy Policy provides additional clarification on what data we collect, why we require it, and how we handle it, and we have made sure to use clear and easy to understand language rather than standard legal vocabulary. Since we were the first to offer free antivirus protection to users worldwide, we made the decision to voluntarily apply compliance with the General Data Protection Regulation (GDPR) and California Consumer Privacy Act (CCPA) privacy requirements across our entire global user base – without exception. Our Consent Policy explains the steps a user can take to give or withdraw their consent at any time for our products and for trend analytics created by Jumpshot.
Another 12% down today. Once it stabilises, I'll buy back in.
They entered into negotiations t o sell Jumpshot to ASCL t the beginning of last year. They received £30 million in August. ASCL have the option to purchase the rest of Jumpshot for up to £300 million. It s a great business deal. An apt comment on AVST on Engadget: We looked at their product a year ago and it was all aggregated and anonymised. No user-level data, no way any one person could be identified.
Just "here's how many people we estimate are on your website each month".
Yawn. One more fearmongering article trying to get clicks over nothing.
So Avast agrees that its ownership of Jumpsuit is incompatible with the aims of a cyber security. How long did it take them to work that one out?
Pretty poor response in honesty